BOOKS BY CATEGORY
Your Account
Stem Cells and Cancer
Price
Quantity
€170.79
(To see other currencies, click on price)
Paperback / softback
Add to basket  

€243.99
(To see other currencies, click on price)
Add to basket  

MORE ABOUT THIS BOOK

Main description:

Significance of Stem Cells to Tumor Development

Cancer stem cells remain a controversial topic and the criteria that define cancer stem cells are continuing to evolve. A recent surge in stem cell research has ignited a field of discovery into many human diseases including diabetes, neuropathologies, and cancer. By replacing specific differentiated cells that have either been lost or died, stem cell therapy proves to be a very promising approach to the treatment of many debilitating diseases. Though stem cells may provide therapeutic benefit under certain conditions, they are also often implicated in the initiation, progression, and therapeutic resistance of malignant disease.

This first edition of Stem Cells and Cancer is intended to give a current perspective on the role of stem cells in cancer and strategies for novel therapies directed toward tumor stem cells. The current cancer stem cell hypothesis is presented in several chapters with distinctions made between the hierarchical and stochastic models of tumor cell development. "Stemness," self-renewal, pluripotency, clonality, and tumorigenicity are important concepts applied towards defining cancer stem cells. Signaling pathways such as Wnt, Sonic Hedgehog, Notch, and Bmi-1 that are involved in differentiation, proliferation, and survival are implicated in the malignant process. Additional chapters address the identification of cancer stem cell populations through the evaluation of molecular markers such as CD133, CD44, and CD24, for example, or by Hoescht dye exclusion to recognize 'side populations.' Mesenchymal and hematopoietic stem cells are described as well as mouse models that are employed to elucidate the properties and functionality of stem cells in cancer and the stem cell niche. This book encompasses a wide variety of human cancers that include but are not limited to leukemia, gliomas, breast, and prostate cancers. Resistance to conventional therapies, genetic versus epigenetic changes that affect therapeutic response and strategies to prevent disease recurrence are challenges have been incorporated into this volume. Stem Cells and Cancer represents a compendium of cutting edge research by experts in the field and will be instrumental in the study of this intriguing line of investigation for many years to come.

Rebecca Bagley is a senior scientist at Genzyme Corporation and has worked in the biotechnology industry for 20 years with degrees in biology from Wellesley College and Harvard University. Her expertise in drug development spans a wide range of approaches including immunotherapies, gene and protein therapies, and small molecule delivery with publications in journals such as Molecular Cancer Therapeutics, Cancer Research, and Microvascular Research . Her current research focuses on stem cells, tumor vasculature, and target validation.

Dr. Beverly A. Teicher is Vice President of Oncology Research at Genzyme Corporation. Dr. Teicher completed a PhD in Bioorganic Chemistry at the Johns Hopkins University and postdoctoral training at Yale University School of Medicine. Dr. Teicher joined Dana-Farber Cancer Institute as an Assistant Professor of Pathology and rose to Associate Professor of Medicine and Radiation Therapy, Harvard Medical School at Dana-Farber Cancer Institute and Joint Center for Radiation Therapy. Dr. Teicher is an active member of the international scientific community having authored or co-authored more than 400 scientific publications. She has edited eight books, is senior editor for the journal Clinical Cancer Research and is series editor for the Cancer Drug Discovery and Development book series.


Contents:

Table of Contents
Introduction - Cancer Stem Cells vs. Normal Stem Cells
Rebecca Bagley, MS, Genzyme Corporation
Chapter 1: Stem Cell Microenvironment - Hematopoietic Stem Cells
Linheng Li, PhD, Stowers Institute for Medical Research
Tannishtha Reya, PhD, Duke University Medical Center
David Scadden, MD, Center for Regenerative Medicine, Mass General Hospital
Sean Morrison, PhD, University of Michigan Medical School
Chapter 2: Tumor Niche/Microenvironment - Mesenchymal Stem Cells
Paul Simmons, PhD, University of Texas Health Science Center
Ajeeta Dash, PhD, Genzyme Corporation
Chapter 3: Cancer Stem Cells - Brain Tumors
Peter Dirks, PhD, MD, University of Toronto Hospital for Sick Children
Jeremey Rich, MD, Duke University Medical Center
Nobuko Uchida, PhD, Stem Cells, Inc.
Sheila Singh, MD, University of Toronto Hospital for Sick Children
Chapter 4: Cancer Stem Cells - Breast Carcinoma
Jane Visvader, PhD, Victorian Breast Cancer Research Consortium
Max Wicha, MD, University of Michigan Comprehensive Cancer Center
Michael Clarke, MD, Stanford University Stem and Regenerative Medicine Institute
Connie Eaves, PhD, British Columbia Cancer Research Centre
Chapter 5: Cancer Stem Cells - Lung Cancers
Carla Bender Kim, PhD, Children's Hospital/Harvard University
Joan Schiller, MD, Southwestern Medical School/Simmons Comprehensive Cancer Center
Jaclyn Hung, PhD, British Columbia Cancer Research Centre
Chapter 6: Cancer Stem Cells - Pancreatic Cancer
Diane Simeone, MD, University of Michigan Medical Center
Chapter 7: Cancer Stem Cells - Ovarian
Paul Szotek, MD, Mass General Hospital, Harvard Medical School
Chapter 8: Cancer Stem Cells - Colon
Michael Clarke, MD, Stanford University Stem and Regenerative Medicine Institute
Hans Clevers,MD/PhD, Netherlands Institute for Developmental Biology
Chapter 9: Cancer Stem Cells - Prostate Cancer
Owen Witte/Susan Kasper
Chapter 10: Epidermal Stem Cells
Elaine Fuchs, PhD, Rockefeller University
Fiona Watt, PhD, Cancer Resarch UK London, Cambridge Institute
Chapter 11: Hematopoietic Stem Cells in Blood Cancers: Leukemia / Myeloma / Lymphoma
Catriona Jamieson, MD/PhD, University of California Medical Center
Daniel Tenen, MD, Beth Israel Deaconess Medical Center, Harvard Medical School
Dominique Bonnet, PhD, London Research Institute
Michael Becker, MD, University of Rochester Medical Center
John Dick, PhD, Toronto General Research Institute
Frederick Alt, PhD, Howard Hughes Medical Institute
Michael Cleary, MD, Stanford University School of Medicine
Irving Weissman, MD/PhD, Stanford University School of Medicine
Craig Jordan, PhD, University of Rochester Medical Center
Chapter 12: Epigenetic Control and Chromosomal Instability
Laurie Jackson-Grusby, PhD, Children's Hospital, Harvard Medical School
Kornelia Polyak, MD/PhD, Dana-Farber Cancer Institute
Bradley Bernstein, MD/PhD, Mass General Hospital, Harvard Medical School
Stephen Baylin, MD, Johns Hopkins School of Medicine
Chapter 13: Signaling Pathways
Roeland Nusse, PhD, Stanford University
Andreas Androutsellis-Theotokis, PhD, National Institute of Health
Ivan Maillard, PhD, University of Pennsylvania School of Medicine
Tannishtha Reya, PhD, Duke University Medical Center
Linheng Li, Stowers, PhD, Institute for Medical Research
Chapter 14: Targeting Cancer Stem Cells: A New Therapeutic Approach
Tessa Holyoake, PhD, University of Glasgow
D. Gary Gilliland, MD/PhD, Howard Hughes Medical Institute
Jeffrey Molldrem, MD, M. D. Anderson Cancer Center
Vera Donnenberg, PhD, McGowan Institute for


PRODUCT DETAILS

ISBN-13: 9781617379208
Publisher: Springer (Humana Press Inc.)
Publication date: December, 2010
Pages: 362
Weight: 851g
Availability: Available
Subcategories: Oncology, Pharmacology
Related books
Publisher recommends
Related books
From the same series

CUSTOMER REVIEWS

Average Rating